prikaz prve stranice dokumenta Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
  Preuzmi
PDF 397.4 KB
Znanstveni rad - Pregledni rad
Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
Diabetology, 5 (2024), 4; 406-429. https://doi.org/10.3390/diabetology5040031
Knežević, Sandra; Filippi-Arriaga, Francesca; Belančić, Andrej; Božina, Tamara; Mršić-Pelčić, Jasenka; Vitezić, Dinko

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Knežević, S., Filippi Arriaga, F., Belančić, A., Božina, T., Mršić Pelčić, J. i Vitezić, D. (2024). Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review. Diabetology, 5. (4), 406-429. doi: 10.3390/diabetology5040031

Knežević, Sandra, et al. "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review." Diabetology, vol. 5, br. 4, 2024, str. 406-429. https://doi.org/10.3390/diabetology5040031

Knežević, Sandra, Francesca Filippi Arriaga, Andrej Belančić, Tamara Božina, Jasenka Mršić Pelčić i Dinko Vitezić. "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review." Diabetology 5, br. 4 (2024): 406-429. https://doi.org/10.3390/diabetology5040031

Knežević, S., et al. (2024) 'Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review', Diabetology, 5(4), str. 406-429. doi: 10.3390/diabetology5040031

Knežević S, Filippi Arriaga F, Belančić A, Božina T, Mršić Pelčić J, Vitezić D. Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review. Diabetology [Internet]. 03.09.2024. [pristupljeno 29.12.2024.];5(4):406-429. doi: 10.3390/diabetology5040031

S. Knežević, F. Filippi Arriaga, A. Belančić, T. Božina, J. Mršić Pelčić i D. Vitezić, "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review", Diabetology, vol. 5, br. 4, str. 406-429, Rujan 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:491768. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:491768
Podaci o radu
Naslov (engleski)Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
AutorSandra Knežević
AutorFrancesca Filippi-Arriaga
AutorAndrej Belančić
AutorTamara Božina
AutorJasenka Mršić-Pelčić
AutorDinko Vitezić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Sažetak (engleski)
Metabolic syndrome (MetS) presents a significant global health challenge, characterized by a cluster of metabolic alterations including obesity, hypertension, insulin resistance/dysglycemia, and atherogenic dyslipidemia. Advances in understanding and pharmacotherapy have added complexity to MetS management, particularly concerning drug interactions and pharmacogenetic variations. Limited literature exists on drug–drug–gene interactions (DDGIs) and drug–drug–transporter gene interactions (DDTGIs), which can significantly impact pharmacokinetics and pharmacodynamics, affecting treatment outcomes. This narrative review aims to address the following three key objectives: firstly, shedding a light on the PK metabolism, transport, and the pharmacogenetics (PGx) of medicines most commonly used in the MetS setting (relevant lipid-lowering drugs, antihypertensives and antihyperglycemics agents); secondly, exemplifying potential clinically relevant pharmacokinetic drug interactions, including drug–drug interactions, DDGIs, and DDTGIs; and, thirdly, describing and discussing their potential roles in clinical practice. This narrative review includes relevant information found with the use of interaction checkers, pharmacogenetic databases, clinical pharmacogenetic practice guidelines, and literature sources, guided by evidence-based medicine principles.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology
Brojčani podacivol. 5, br. 4, str. 406-429
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology5040031
URN:NBNurn:nbn:hr:184:491768
Datum objave publikacije2024-09-03
URL dokumentahttps://www.mdpi.com/2673-4540/5/4/31
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-09-13 11:02:35